Astrazeneca (NYSE:AZN) Posts Earnings Results

Astrazeneca (NYSE:AZN) issued its quarterly earnings results on Monday. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.10 by $0.53, FiscalAI reports. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion.

Astrazeneca Price Performance

Astrazeneca stock opened at $168.68 on Monday. The stock has a market capitalization of $261.61 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 1.38 and a beta of 0.24. Astrazeneca has a 52-week low of $142.98 and a 52-week high of $212.71. The stock’s 50 day moving average price is $180.55 and its two-hundred day moving average price is $188.07. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Triumph Capital Management bought a new position in Astrazeneca during the third quarter worth $25,000. JPL Wealth Management LLC bought a new stake in Astrazeneca in the third quarter valued at $35,000. Johnson Financial Group Inc. increased its stake in Astrazeneca by 1,265.0% in the third quarter. Johnson Financial Group Inc. now owns 546 shares of the company’s stock valued at $42,000 after purchasing an additional 506 shares in the last quarter. Acumen Wealth Advisors LLC acquired a new position in shares of Astrazeneca during the fourth quarter valued at about $47,000. Finally, Binnacle Investments Inc raised its holdings in shares of Astrazeneca by 21.8% during the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after purchasing an additional 118 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings downgraded shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.